Equities research analysts forecast that Emergent Biosolutions Inc (NYSE:EBS) will post sales of $182.16 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Emergent Biosolutions’ earnings. The lowest sales estimate is $179.71 million and the highest is $184.60 million. Emergent Biosolutions reported sales of $151.66 million during the same quarter last year, which indicates a positive year-over-year growth rate of 20.1%. The company is expected to report its next quarterly earnings results on Thursday, February 22nd.
According to Zacks, analysts expect that Emergent Biosolutions will report full-year sales of $182.16 million for the current year. For the next fiscal year, analysts forecast that the company will report sales of $715.70 million per share. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that follow Emergent Biosolutions.
Emergent Biosolutions (NYSE:EBS) last issued its earnings results on Thursday, November 2nd. The biopharmaceutical company reported $0.73 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.32. The company had revenue of $149.43 million during the quarter, compared to analysts’ expectations of $124.55 million. Emergent Biosolutions had a return on equity of 15.20% and a net margin of 15.60%. Emergent Biosolutions’s quarterly revenue was up 4.6% compared to the same quarter last year. During the same period in the prior year, the business posted $0.56 EPS.
Shares of Emergent Biosolutions (NYSE:EBS) traded up $1.59 during mid-day trading on Friday, reaching $51.19. The company had a trading volume of 363,681 shares, compared to its average volume of 341,653. The stock has a market cap of $2,110.00, a PE ratio of 31.99, a PEG ratio of 1.01 and a beta of 1.29. Emergent Biosolutions has a 52 week low of $27.94 and a 52 week high of $51.25. The company has a debt-to-equity ratio of 0.38, a current ratio of 7.37 and a quick ratio of 6.46.
In other Emergent Biosolutions news, CEO Daniel Abdun-Nabi sold 31,508 shares of the stock in a transaction that occurred on Friday, November 3rd. The stock was sold at an average price of $42.77, for a total value of $1,347,597.16. Following the completion of the sale, the chief executive officer now owns 215,642 shares in the company, valued at approximately $9,223,008.34. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Chairman Fuad El-Hibri sold 40,000 shares of the stock in a transaction that occurred on Tuesday, November 14th. The stock was sold at an average price of $40.37, for a total value of $1,614,800.00. The disclosure for this sale can be found here. Insiders have sold a total of 206,329 shares of company stock valued at $8,892,362 over the last 90 days. 16.50% of the stock is currently owned by company insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Riverhead Capital Management LLC lifted its holdings in Emergent Biosolutions by 102.8% in the 2nd quarter. Riverhead Capital Management LLC now owns 3,042 shares of the biopharmaceutical company’s stock worth $103,000 after buying an additional 1,542 shares during the period. Ameritas Investment Partners Inc. lifted its holdings in Emergent Biosolutions by 23.2% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,118 shares of the biopharmaceutical company’s stock worth $106,000 after buying an additional 587 shares during the period. First Quadrant L P CA purchased a new stake in Emergent Biosolutions in the 3rd quarter worth approximately $157,000. Meeder Asset Management Inc. lifted its holdings in Emergent Biosolutions by 94.7% in the 3rd quarter. Meeder Asset Management Inc. now owns 4,732 shares of the biopharmaceutical company’s stock worth $191,000 after buying an additional 2,302 shares during the period. Finally, Victory Capital Management Inc. purchased a new position in shares of Emergent Biosolutions in the 3rd quarter valued at approximately $191,000. Institutional investors and hedge funds own 88.44% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/01/20/emergent-biosolutions-inc-ebs-expected-to-post-quarterly-sales-of-182-16-million.html.
About Emergent Biosolutions
Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.